CELGENE CORP /DE/ CELG Cash Flow

Celgene corp /de/ (CELG)

CashFlow / TTM

Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09	Jun'09	Mar'09
Cash flows from operating activities:
Net income
5,880	5,271	4,745	4,046	2,892	2,798	2,854	2,940	3,450	2,633	2,130	1,999	2,131	1,925	1,684	1,602	1,654	2,197	2,439	1,999	1,600	1,464	1,344	1,449	1,498	1,550	1,439	1,456	1,603	1,552	1,463	1,317	1,116	1,024	900	880	925	860	848	776	0	0	0
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation
183	175	169	160	153	147	140	134	131	129	124	121	118	115	115	115	112	110	106	104	103	101	99	96	96	93	89	84	78	74	72	71	68	63	59	54	50	47	44	41	0	0	0
Amortization
473	479	497	475	428	380	341	337	362	366	355	384	370	347	333	287	255	260	260	265	275	277	281	277	270	247	224	198	208	238	264	291	284	255	232	204	152	127	102	84	0	0	0
Impairment charges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49	0	0	0	-	-	-	-	105	101	144	135	148	64	22	22	118	0	0	0	-	-	-	-	-	-	-	-
Allocation of prepaid royalties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26	38	44	47	47	43	40	36	0	0	0
Provision for accounts receivable allowances
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17	10	8	6	2	0	-0	-2	-2	-1	0	2	0	0	0
Deferred income taxes
22	-4	43	32	-1,145	-1,187	-1,302	-1,330	-282	-363	-381	-344	123	52	30	-33	-436	-343	-298	-272	-333	-332	-273	-246	-204	-169	213	100	159	174	-187	-85	-168	-154	-158	-103	-28	-40	-25	-26	0	0	0
Change in value of contingent consideration and success payments
-73	25	79	19	-1,351	-1,399	-1,419	-1,350	84	58	27	21	21	-8	6	-8	20	28	59	48	102	134	146	171	272	237	187	166	-296	-284	-234	-147	129	112	94	-9	0	0	0	-	-	-	-
Gain on sale of business
-	-	-	-	-	-	-	-	-	-	-	38	38	38	38	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss on sales of debt securities available-for-sale
0	0	0	-18	43	43	43	61	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value adjustments on equity investments
-613	-515	-373	317	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Share-based compensation expense
848	911	970	921	893	813	699	644	636	625	613	606	602	604	594	577	554	516	472	447	417	398	364	325	287	252	239	231	225	219	215	217	211	208	200	182	174	164	154	145	0	0	0
Equity in (gains) losses of affiliated companies
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-2	-0	0	0	0
Share-based employee benefit plan expense
0	13	24	33	32	32	33	34	46	42	41	40	39	37	36	35	35	40	41	40	36	36	32	32	29	25	23	19	21	20	20	20	17	15	14	14	13	12	14	11	0	0	0
Derivative, Gain (Loss) on Derivative, Net
-45	-26	-33	-3	-47	-20	-43	-72	10	-243	-155	-169	-201	35	-3	25	92	63	63	54	9	-2	-0	8	136	123	105	79	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized change in value of derivative instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-34	-49	-28	-71	0	0	0	-	-	-	-53	-57	-30	-33	18	9	0	0	0
Realized losses (gains) on marketable securities available for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	5	3	0	4	5	11	16	19	40	31	0	0	0
Other, net
75	43	15	15	20	-12	22	24	19	58	9	10	5	-31	-24	-26	-16	10	7	9	6	-1	-4	-11	-24	-25	-22	-11	-18	-7	-12	-15	0	-2	-4	-3	-14	-13	-9	-8	0	0	0
Change in current assets and liabilities, excluding the effect of acquisitions and disposals:
Accounts receivable
284	406	402	178	322	318	300	236	217	216	228	222	303	245	222	305	266	245	216	166	8	88	24	101	134	142	37	30	109	99	266	263	264	287	256	234	193	159	207	122	0	0	0
Inventory
-58	-91	-92	-82	-26	24	26	42	30	42	39	55	85	76	84	51	50	56	42	56	60	63	70	89	86	80	70	69	49	28	-4	-71	-98	-83	-59	-18	22	14	1	-1	0	0	0
Other operating assets
-219	-339	-166	55	162	212	273	73	328	190	-84	-94	171	179	260	326	20	30	3	-52	-14	0	96	90	140	156	-26	-91	-67	-114	-7	66	6	70	34	45	21	-12	42	53	0	0	0
Assets held for sale, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Accounts payable and other operating liabilities
440	505	481	290	179	-90	419	273	483	783	384	619	440	505	337	527	410	331	182	234	210	169	481	287	119	216	26	68	200	175	247	191	52	0	-15	51	109	53	-10	0	0	0	0
Income tax payable
-106	54	-348	-393	2,042	2,018	2,215	2,229	308	238	283	301	476	425	368	362	55	47	43	39	63	71	61	57	35	-65	-478	-455	-453	-328	101	95	133	121	91	78	43	47	78	39	0	0	0
Payment of contingent consideration
29	29	13	22	22	22	22	0	0	0	0	-	-	-	-	-	-	-	-	14	80	80	80	75	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-57	-16	47	41	44	39	11	20	19	11	6	7	-1	2	37	37	45	30	5	8	-3	12	19	16	37	15	2	5	0	5	9	-1	10	11	12	20	8	6	5	3	0	0	0
Net cash provided by operating activities
8,158	7,910	6,972	5,171	4,517	3,681	4,068	5,246	4,959	4,641	4,018	4,165	4,122	3,637	2,928	2,785	2,258	2,874	3,105	2,806	2,524	2,194	2,415	2,225	2,154	2,155	2,041	2,018	1,976	2,007	1,845	1,776	1,543	1,322	1,172	1,181	1,297	1,192	1,067	909	0	0	0
Cash flows from investing activities:
Proceeds from sales of debt securities available-for-sale
981	522	446	3,388	5,965	7,055	8,809	5,872	3,381	2,262	585	633	680	2,648	3,034	3,800	4,175	2,611	2,667	2,175	3,368	3,457	3,334	3,642	2,491	2,222	2,154	1,743	1,548	1,930	1,861	2,175	0	0	0	-	-	-	-	-	-	-	-
Purchases of debt securities available-for-sale
928	1,055	1,041	675	1,687	4,862	6,434	8,163	7,262	4,085	2,612	1,106	749	1,193	1,495	1,889	2,223	2,232	2,573	2,661	2,883	3,766	3,634	3,983	4,488	3,781	3,778	2,768	1,883	1,491	1,300	1,693	0	0	0	-	-	-	-	-	-	-	-
Capital expenditures
295	291	311	330	335	315	305	279	242	265	238	236	310	294	303	286	194	183	167	150	127	119	119	119	122	113	108	111	123	138	137	132	130	111	102	98	92	94	91	93	0	0	0
Proceeds from sales of equity investment securities
20	44	43	96	180	144	171	116	0	0	0	-	-	-	-	92	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in affiliated companies
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	1	3	3	3	0	0	0
Purchases of equity investment securities
180	190	192	249	194	409	451	410	577	373	305	307	178	162	324	273	225	245	77	67	77	59	59	47	27	11	30	30	95	87	63	59	0	0	0	-	-	-	-	-	-	-	-
Proceeds from sales of marketable securities available for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Purchases of marketable securities available for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Payments for acquisition of business, net of cash acquired
0	0	0	8,648	8,648	8,648	8,648	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	352	0	0	0	-	-	-	-	2,652	0	0	0	-	-	-	0
Payment for acquisition of intangible asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	24	39	18	19	20	-13	-13	-14	-14	0	0	0	-	-	-	-	-	-	-	-	-3	0	0	0
Purchases of investment securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Net cash (used in) investing activities
-802	-970	-1,055	-6,418	-4,719	-7,062	-6,889	-2,891	-4,693	-2,431	-2,552	-1,002	-659	-6,684	-6,707	-6,259	-5,970	7	-879	-1,438	-450	-1,207	-497	-528	-2,218	-1,730	-1,798	-1,553	-712	-141	95	377	-2,592	-1,161	-1,468	-2,107	471	-1,099	-908	-856	0	0	0
Cash flows from financing activities:
Payment for treasury shares
0	0	3,396	6,096	9,004	9,118	6,240	3,833	1,059	1,265	1,043	2,160	2,708	2,965	3,654	3,257	3,115	2,790	2,419	2,975	3,130	3,068	3,289	2,764	2,630	3,174	2,884	2,043	2,095	2,246	1,941	2,188	0	0	0	-	-	-	-	-	-	-	-
Proceeds from short-term borrowing
0	780	3,894	5,709	5,709	4,929	1,815	0	0	0	0	-	-	-	-	6,111	2,360	1,302	1,196	2,566	3,137	3,486	4,499	4,462	4,381	5,081	4,871	4,494	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Principal repayments on short-term borrowing
-1	1,775	3,894	5,709	5,710	3,934	1,815	0	0	0	0	-	-	-	-	6,213	1,761	633	2,066	3,012	3,443	4,182	3,993	4,227	4,302	4,586	4,660	4,712	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of long-term debt
0	0	0	4,452	7,424	7,920	7,920	3,468	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of contingent consideration
-42	-42	-18	0	-40	-40	-40	0	0	2	5	8	-11	-9	-11	-9	14	11	14	10	7	6	2	1	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25	240	240	240	225	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from share-based compensation arrangements
378	359	184	144	177	344	545	685	805	670	481	359	238	223	199	252	296	307	352	297	298	325	344	551	613	555	527	476	395	353	363	166	123	96	73	86	71	78	69	49	0	0	0
Excess tax benefit from share-based compensation arrangements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	347	334	305	250	176	178	162	169	168	101	67	49	35	49	44	31	42	30	28	36	6	44	65	97	0	0	0
Net cash (used in) financing activities
-203	-1,218	-3,270	-1,540	-2,848	-1,803	281	-1,584	-299	-634	-598	-1,834	-3,941	3,610	3,846	4,283	6,045	-1,478	-157	-417	-723	455	-1,034	-553	-290	-535	-592	-248	-279	-1,610	-1,539	-1,622	20	597	706	1,177	-87	-92	-74	-61	0	0	0
Effect of currency rate changes on cash and cash equivalents
-29	-11	-33	8	19	27	86	72	21	21	-40	-39	-15	-30	9	-51	-59	-92	-97	-63	-31	34	17	0	62	-9	-16	14	-64	-40	-27	-23	-8	33	21	-2	-0	-11	17	17	0	0	0
Net increase (decrease) in cash and cash equivalents
7,124	5,711	2,614	-2,779	-3,031	-5,157	-2,454	843	-12	1,597	828	1,290	-493	531	76	758	2,274	1,311	1,971	887	1,319	1,477	901	1,144	-292	-120	-365	230	920	214	374	508	-1,037	792	431	248	1,680	-11	101	9	0	0	0
Supplemental schedule of non-cash investing and financing activity:
Change in net unrealized (gain) loss on debt securities available-for-sale
-19	-19	-18	-9	1,293	849	847	611	-875	-439	-408	-563	-241	-659	-619	-315	-137	353	332	494	185	284	287	205	220	55	5	1	-1	-0	-2	-3	-1	-3	-11	-13	-11	-17	-8	-3	0	0	0
Matured shares tendered in connection with stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-8	-9	-1	-2	-2	0	0	0
Supplemental disclosure of cash flow information:
Interest paid
779	779	780	689	659	577	531	539	525	524	524	527	534	387	393	243	241	240	194	196	149	120	120	90	90	69	69	48	0	0	0	-	-	-	-	1	0	0	0	-	-	-	-
Income taxes paid
694	710	1,053	1,165	999	928	734	475	478	479	399	373	360	340	356	361	365	348	304	294	340	330	311	291	326	452	460	469	383	198	145	93	85	105	114	121	124	101	68	70	0	0	0
Human Longevity
Investment in Human Longevity, Inc. common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	0	40	-	0	0	0	90	90	90	90	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-